176 related articles for article (PubMed ID: 24446873)
1. Identification of clinically important chromosomal aberrations in acute myeloid leukemia by array-based comparative genomic hybridization.
Mehrotra M; Luthra R; Ravandi F; Sargent RL; Barkoh BA; Abraham R; Mishra BM; Medeiros LJ; Patel KP
Leuk Lymphoma; 2014 Nov; 55(11):2538-48. PubMed ID: 24446873
[TBL] [Abstract][Full Text] [Related]
2. The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia--analysis of 848 patients.
Visani G; Bernasconi P; Boni M; Castoldi GL; Ciolli S; Clavio M; Cox MC; Cuneo A; Del Poeta G; Dini D; Falzetti D; Fanin R; Gobbi M; Isidori A; Leoni F; Liso V; Malagola M; Martinelli G; Mecucci C; Piccaluga PP; Petti MC; Rondelli R; Russo D; Sessarego M; Specchia G; Testoni N; Torelli G; Mandelli F; Tura S
Leukemia; 2001 Jun; 15(6):903-9. PubMed ID: 11417475
[TBL] [Abstract][Full Text] [Related]
3. Loss of genetic material is more common than gain in acute myeloid leukemia with complex aberrant karyotype: a detailed analysis of 125 cases using conventional chromosome analysis and fluorescence in situ hybridization including 24-color FISH.
Schoch C; Haferlach T; Bursch S; Gerstner D; Schnittger S; Dugas M; Kern W; Löffler H; Hiddemann W
Genes Chromosomes Cancer; 2002 Sep; 35(1):20-9. PubMed ID: 12203786
[TBL] [Abstract][Full Text] [Related]
4. Correlation between CD34 expression and chromosomal abnormalities but not clinical outcome in acute myeloid leukemia.
Fruchart C; Lenormand B; Bastard C; Boulet D; Lesesve JF; Callat MP; Stamatoullas A; Monconduit M; Tilly H
Am J Hematol; 1996 Nov; 53(3):175-80. PubMed ID: 8895688
[TBL] [Abstract][Full Text] [Related]
5. Prognostic implications of chromosome 17 abnormalities in the context of monosomal karyotype in patients with acute myeloid leukemia and complex cytogenetics.
Nazha A; Kantarjian HM; Bhatt VR; Nogueras-Gonzalez G; Cortes JE; Kadia T; Garcia-Manero G; Abruzzo L; Daver N; Pemmaraju N; Quintas-Cardama A; Ravandi F; Keating M; Borthakur G
Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):163-71. PubMed ID: 24461514
[TBL] [Abstract][Full Text] [Related]
6. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study.
Slovak ML; Kopecky KJ; Cassileth PA; Harrington DH; Theil KS; Mohamed A; Paietta E; Willman CL; Head DR; Rowe JM; Forman SJ; Appelbaum FR
Blood; 2000 Dec; 96(13):4075-83. PubMed ID: 11110676
[TBL] [Abstract][Full Text] [Related]
7. Chromosomal minimal critical regions in therapy-related leukemia appear different from those of de novo leukemia by high-resolution aCGH.
Itzhar N; Dessen P; Toujani S; Auger N; Preudhomme C; Richon C; Lazar V; Saada V; Bennaceur A; Bourhis JH; de Botton S; Bernheim A
PLoS One; 2011 Feb; 6(2):e16623. PubMed ID: 21339820
[TBL] [Abstract][Full Text] [Related]
8. Acquired genomic copy number aberrations and survival in adult acute myelogenous leukemia.
Parkin B; Erba H; Ouillette P; Roulston D; Purkayastha A; Karp J; Talpaz M; Kujawski L; Shakhan S; Li C; Shedden K; Malek SN
Blood; 2010 Dec; 116(23):4958-67. PubMed ID: 20729466
[TBL] [Abstract][Full Text] [Related]
9. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial.
Grimwade D; Walker H; Harrison G; Oliver F; Chatters S; Harrison CJ; Wheatley K; Burnett AK; Goldstone AH;
Blood; 2001 Sep; 98(5):1312-20. PubMed ID: 11520776
[TBL] [Abstract][Full Text] [Related]
10. Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry.
Guerci A; Merlin JL; Missoum N; Feldmann L; Marchal S; Witz F; Rose C; Guerci O
Blood; 1995 Apr; 85(8):2147-53. PubMed ID: 7536492
[TBL] [Abstract][Full Text] [Related]
11. Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia.
Giles FJ; Kantarjian HM; Cortes JE; Garcia-Manero G; Verstovsek S; Faderl S; Thomas DA; Ferrajoli A; O'Brien S; Wathen JK; Xiao LC; Berry DA; Estey EH
J Clin Oncol; 2003 May; 21(9):1722-7. PubMed ID: 12721247
[TBL] [Abstract][Full Text] [Related]
12. Induction chemotherapy versus palliative treatment for acute myeloid leukemia in a consecutive cohort of elderly patients.
Colovic M; Colovic N; Radojkovic M; Stanisavljevic D; Kraguljac N; Jankovic G; Tomin D; Suvajdzic N; Vidovic A; Atkinson HD
Ann Hematol; 2012 Sep; 91(9):1363-70. PubMed ID: 22592651
[TBL] [Abstract][Full Text] [Related]
13. Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients.
Schoch C; Haferlach T; Haase D; Fonatsch C; Löffler H; Schlegelberger B; Staib P; Sauerland MC; Heinecke A; Büchner T; Hiddemann W;
Br J Haematol; 2001 Jan; 112(1):118-26. PubMed ID: 11167792
[TBL] [Abstract][Full Text] [Related]
14. The impact of abn(17p) and monosomy -5/del(5q) on the prognostic value of the monosomal karyotype in acute myeloid leukemia.
Breems DA; Van Putten WL; Löwenberg B
Blood; 2013 Apr; 121(15):3056-7. PubMed ID: 23580638
[No Abstract] [Full Text] [Related]
15. High-dose cytarabine, idarubicin, and granulocyte colony-stimulating factor remission induction therapy for previously untreated de novo and secondary adult acute myeloid leukemia.
Baer MR; Christiansen NP; Frankel SR; Brunetto VL; Mrózek K; Bloomfield CD; Herzig GP
Semin Oncol; 1993 Dec; 20(6 Suppl 8):6-12. PubMed ID: 7507264
[TBL] [Abstract][Full Text] [Related]
16. A genome-wide single-nucleotide polymorphism-array can improve the prognostic stratification of the core binding factor acute myeloid leukemia.
Huh J; Kim HJ; Jung CW; Kim HJ; Kim SH; Kim YK; Kim HJ; Shin MG; Moon JH; Sohn SK; Kim SH; Lee WS; Won JH; Mun YC; Kim H; Park J; Min WS; Kim DH;
Am J Hematol; 2012 Oct; 87(10):961-8. PubMed ID: 22886749
[TBL] [Abstract][Full Text] [Related]
17. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.
Bloomfield CD; Lawrence D; Byrd JC; Carroll A; Pettenati MJ; Tantravahi R; Patil SR; Davey FR; Berg DT; Schiffer CA; Arthur DC; Mayer RJ
Cancer Res; 1998 Sep; 58(18):4173-9. PubMed ID: 9751631
[TBL] [Abstract][Full Text] [Related]
18. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties.
Grimwade D; Walker H; Oliver F; Wheatley K; Harrison C; Harrison G; Rees J; Hann I; Stevens R; Burnett A; Goldstone A
Blood; 1998 Oct; 92(7):2322-33. PubMed ID: 9746770
[TBL] [Abstract][Full Text] [Related]
19. High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML).
Larson SM; Campbell NP; Huo D; Artz A; Zhang Y; Gajria D; Green M; Weiner H; Daugherty C; Odenike O; Godley LA; Hyjek E; Gurbuxani S; Thirman M; Sipkins D; Van Besien K; Larson RA; Stock W
Leuk Lymphoma; 2012 Mar; 53(3):445-50. PubMed ID: 21913806
[TBL] [Abstract][Full Text] [Related]
20. The influence of age on prognosis of de novo acute myeloid leukemia differs according to cytogenetic subgroups.
Schoch C; Kern W; Schnittger S; Büchner T; Hiddemann W; Haferlach T
Haematologica; 2004 Sep; 89(9):1082-90. PubMed ID: 15377469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
